Vasculitis trials

ACQUIVAS

Vasculitis means inflammation of any of your blood vessels. It can cause a variety of different symptoms and problems. One type of vasculitis, called antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, also known as AAV, is…

ALEVIATE

Anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) is a severe disease of unknown cause when the immune system attacks and injures various tissues in the body. Patients with AAV develop kidney and lung disease and their lives…

BIOVAS

The vasculitis diseases occur when the body's immune system attacks blood vessels, causing injury to the vessel and the part of the body it supplies with blood. Vasculitis is rare, there are a number of different types, and they affect both…

COMBIVAS

Dual B-cell targeted immunotherapy with B cell depletion (rituximab) and BAFF antagonism (belimumab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms. COMBIVAS is a randomized, double blind, placebo-…

MYCYC

There is a clear need for improved therapy in ANCA associated vasculitis where current treatments are toxic and contribute to poor outcomes. Conventional therapy combines cyclophosphamide with prednisolone but is associated with severe adverse…

PEXIVAS

Granulomatosis with polyangiitis (Wegener's) (WG) and microscopic polyangiitis (MPA) are syndromes of primary systemic vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA). Together, these syndromes are grouped as ANCA-…

RITAZAREM

Rituximab is now established as an effective drug for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis following major European and US trials reported in 2010. After a time, its effect wears off and the disease can return. This occurs in at…